Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there was a 75% reduction in mortality, RR 0.25 [0.12-0.52],
p = 0.0002.
A sponsor reportedly required the conclusion of this paper to be changed against the wishes of the authors (to suggest that more trials should be done as opposed to the existing evidence being sufficient) [1, 2, 3]. Reportedly, Unitaid had influence over the conclusions [4, 5]. See also [6].
Note that one of the 18 studies in this analysis has since been withdrawn (Elgazzar).
Hill et al., 1/19/2021, preprint, 40 authors.